{"id":"W2548090821","doi":"10.1182/blood.v126.23.2702.2702","title":"Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ibritumomab tiuxetan; Medicine; Mantle cell lymphoma; Radioimmunotherapy; Internal medicine; Clinical endpoint; CHOP; Rituximab; Salvage therapy; Surgery; Gastroenterology; Oncology; Lymphoma; Clinical trial; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002388102,0.0004729081,0.001148397,0.0003130922,0.0004078411,0.0007527837,0.0004724147,0.0006058854,0.00148961],"category_scores_gemma":[0.0009337977,0.0002505665,0.0009609011,0.0003489612,0.0003693434,0.0006517979,0.0005287628,0.001389528,0.0005797785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004419039,"about_ca_system_score_gemma":0.0003749334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007064258,"about_ca_topic_score_gemma":0.0008409254,"domain_scores_codex":[0.9994092,0.0002541103,0.00005125579,0.00008498035,0.00008259121,0.0001178876],"domain_scores_gemma":[0.9989773,0.000168672,0.0003180388,0.0001332231,0.00008607443,0.0003166316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4423583,0.04515894,0.3397111,0.000462609,0.003164158,0.001166337,0.0004892536,0.003927001,0.03696616,0.0002540856,0.005796391,0.1205457],"study_design_scores_gemma":[0.04403432,0.3476456,0.5909751,0.00009070284,0.001595086,0.0009471556,0.000249978,0.001780261,0.006178672,0.0002355954,0.006213897,0.00005368387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961876,0.0008313716,0.000284263,0.00008499043,0.00002954753,0.00033515,0.001234599,0.00001762038,0.0009948318],"genre_scores_gemma":[0.9937634,0.0003352946,0.0002579876,0.000265555,0.00003864154,0.0001747708,0.004225504,0.00000821434,0.0009306957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002388102,"threshold_uncertainty_score":0.01262963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02550816733423285,"score_gpt":0.2893842231177857,"score_spread":0.2638760557835528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}